{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(2)"],"submitter":["Chae YK"],"pubmed_abstract":["<h4>Background</h4>Dual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CCCs), which are rare, aggressive cancers.<h4>Methods</h4>DART is a multicenter, multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks), with primary objective as Response Evaluation Criteria in Solid Tumors (RECIST)-based overall response rate (ORR). Secondary objectives were ORR by immune RECIST (iRECIST), progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease (SD) ≥6 months), and toxicity.<h4>Results</h4>"],"journal":["Journal for immunotherapy of cancer"],"pagination":["e012805"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12911695"],"repository":["biostudies-literature"],"pubmed_title":["DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix."],"pmcid":["PMC12911695"],"pubmed_authors":["McLeod CM","Ryan CW","T Goodrich S","Kim EJ","Cristea M","Ali-Ahmad H","Eskander RN","Robinson WR","O'Malley DM","Backes FJ","Bottsford-Miller JN","Chae YK","Blanke CD","Fagbemi SO","Ahmed A","Siedel J","Moloney-Lineen C","Patel SP","Othus M","Sharon E","Kurnit K","Thomes Pepin J","Chan J","Jaslowski AJ","Kim HS","Streicher H","Sueblinvong T","McCormick C","Chung LI","Hays J","Kurzrock R","Naing A","Chen HX","Scalici J"],"additional_accession":[]},"is_claimable":false,"name":"DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix.","description":"<h4>Background</h4>Dual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CCCs), which are rare, aggressive cancers.<h4>Methods</h4>DART is a multicenter, multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks), with primary objective as Response Evaluation Criteria in Solid Tumors (RECIST)-based overall response rate (ORR). Secondary objectives were ORR by immune RECIST (iRECIST), progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease (SD) ≥6 months), and toxicity.<h4>Results</h4>","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-16T05:03:56.706Z","creation":"2026-07-09T10:36:55.433Z"},"accession":"S-EPMC12911695","cross_references":{"pubmed":["41672597"],"doi":["10.1136/jitc-2025-012805"]}}